Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
about
Molecular properties of bacterial multidrug transportersA mass spectrometry-based assay for improved quantitative measurements of efflux pump inhibitionFluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniaeMolecular detection of antimicrobial resistanceIn vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.Antipneumococcal activities of gemifloxacin compared to those of nine other agentsPrevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory seFluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniaeEfflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteriaIncidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in CroatiaFluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in JapanIn vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureusAntimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.Fluoroquinolone resistance in invasive Streptococcus pyogenes isolates due to spontaneous mutation and horizontal gene transfer.Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United StatesClinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteriaEfflux-mediated resistance identified among norfloxacin resistant clinical strains of group B Streptococcus from South KoreaIn vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniaeGenomic characterization of ciprofloxacin resistance in a laboratory-derived mutant and a clinical isolate of Streptococcus pneumoniae.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Prevalence and antimicrobial resistance of Enterococcus species: a hospital-based study in China.Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine.Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci.A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.
P2860
Q28139376-B858DDE1-6479-44BB-AE9E-E7C9D84E1885Q28547153-B5D0AEE7-3BF0-4B41-B2B2-D95F58BF9CCCQ33594174-5977EA65-5B43-45EB-B4A0-4AE03C6D6A3DQ33715260-1A17B675-3036-4F47-AF5D-481A8A111079Q33975793-3557E816-11C2-42C9-AEF0-3640F238CB2AQ33976279-E6EAF75B-1BF4-465F-81F7-F4C9C0453EA9Q33978324-87C05C7C-FC24-48FD-ABE3-BC6239E1639CQ33978679-EC816ADA-F3C3-4DC0-B773-53735879A5CEQ33978849-E102EDEE-DE6E-4773-BA59-DA0B1D1C010EQ33980313-B88BB847-81EE-4FC8-BE4E-7D86C9FBB88EQ33981750-7A2C9AE8-14C6-4B26-9B5B-3CF8A951FAE4Q33982417-8B64C3F7-FBF4-4F55-9D0A-2AEDE3AC3B92Q34035762-46214662-594D-4FFD-A0D9-C711B2531036Q34110467-919BF424-C3A2-4217-8178-2DF0039C852CQ34113933-F7D8DAAA-B0C1-4094-818A-F3AFA96B7AB6Q34139244-F5669320-486E-454E-B45E-5294832FC321Q34144100-AF8D99BA-AB9E-4686-B983-C57AF2C8AC9BQ34230118-8DBEEEB5-85E7-453A-8325-747E23D491BEQ34301541-ACE96177-C76D-418B-BC56-28FA6C8B47ECQ34352053-D0CEAFD1-5643-4054-9EC6-594646811954Q34352260-6AD9096D-D610-4C6D-A34F-BE55DF8ECF1AQ34502866-FBE55D67-C542-482B-BCFA-BD6AB87BEB3DQ34509660-05730776-16CF-4F17-B1A1-A07F0E554EDBQ34510471-4AC1636B-E4D9-4ACB-8461-9919835B22E7Q34647294-00AC09DD-212E-45E3-9956-3B619ADD3C1DQ34648805-3A9FD8F6-21BA-4841-BBFF-32FFFD73995BQ36048301-C09EC7AE-4A6D-47CC-8C43-DECA4370D853Q36474350-D789CA94-FFB1-4A46-982C-7D87969AA3C3Q37263914-6C49F908-202E-4A16-BC28-CDE9B1355649Q37733449-D191EABC-807A-4CE7-BE4B-CEEF123B57A0Q38758397-7D643ABC-8A09-42B3-802D-5242F026991EQ39465570-32D6C44B-8769-40CF-B0EE-1FEB2F239F62Q39469655-6F35CBC5-B638-4F1B-847A-4C72A18E1547Q39470683-F0765906-6A27-4DCC-BA1A-79DF1B5A63B9Q39471404-0249D229-4061-4A85-81E3-02079C662146Q39471518-D74E8958-5BC0-4326-B2D8-91C8592855D1Q39472017-C6754427-975D-43ED-BA07-87A6557F147AQ39473327-32FA2706-EA7E-48D8-8DC5-BF3AA7659F79Q39475328-DA92EC5F-2B4B-405F-BD8A-1EB508FE254FQ39476686-C93631A4-BE7C-439B-92B8-0666D1658939
P2860
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
description
1998 nî lūn-bûn
@nan
1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Prevalence of a putative efflu ...... s of Streptococcus pneumoniae.
@ast
Prevalence of a putative efflu ...... s of Streptococcus pneumoniae.
@en
type
label
Prevalence of a putative efflu ...... s of Streptococcus pneumoniae.
@ast
Prevalence of a putative efflu ...... s of Streptococcus pneumoniae.
@en
prefLabel
Prevalence of a putative efflu ...... s of Streptococcus pneumoniae.
@ast
Prevalence of a putative efflu ...... s of Streptococcus pneumoniae.
@en
P2093
P2860
P1476
Prevalence of a putative efflu ...... s of Streptococcus pneumoniae.
@en
P2093
P2860
P304
P407
P577
1998-08-01T00:00:00Z